United Guardian Inc.

UG

Nasdaq; chemicals; SIC 2844, Perfumes, Cosmetics & Other Toilet Preparations; CIK 0000101295

B

second fifth of 329 graded peers in the pooled industrial group

rank 77 of 329; percentile 25.0; sampling error 2.7 points; lower is stronger

A B C D E

B, the elk



Scoreboard

Profitability	C percentile 56.4
Solvency	A percentile 6.2
Growth and financing	C/D percentile 62.6
Reliability	0.83 AUC filers with $12.5M to $120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025
Peer failure rate	1.07% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$12.5M to $120M assets total assets $13.1M
Standard universe	inside revenue above $1M and assets above $10M
Warnings	none triggered not computable: fortress balance sheet
Inputs computable	11 of 14
Graded from	filings received through Mar 27, 2026 230 days before the rescan; latest periodic filing 10-Q received Aug 11, 2026
Last close	$9.16 2026-11-10; market equity $42.1M; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Mar 27, 2026

United-Guardian, Inc. ("Company") is a Delaware corporation that, through its Guardian Laboratories division, manufactures, markets and develops specialty cosmetic, personal care and sexual wellness ingredients and a line of healthcare products including pharmaceuticals and medical lubricants. We conduct various research and development ("R&D") activities. Our R&D department primarily develops new and unique specialty cosmetic and sexual wellness ingredients. We develop new products using natural and environmentally friendly raw materials, which is a priority for many of our cosmetic customers.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 56.4						
Gross profitability	39.2%	21.4%		11.8	357	2025-12-31
Return on invested capital	not computable	9.5%				

one or more required annual facts are missing

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Accruals ratio	1.0%	(4.2%)	85.3	396	2025-12-31
Gross margin stability, five years	3.5 pts	2.2 pts	72.1	299	2025-12-31
Solvency, sleeve percentile 6.2					
Twelve-month failure probability	0.03%	0.05%	7.5	41	2026-06-30
Altman Z double-prime	15.38	3.42	3.4	298	2025-12-31
Net debt to EBITDA	not computable	1.86x			
one or more required annual facts are missing					
Interest coverage	not computable	4.16x			
one or more required annual facts are missing					
Current ratio	7.31x	2.20x	7.6	421	2025-12-31
Growth and financing, sleeve percentile 62.6					
Revenue growth, three-year compound	(6.0%)	1.2%	80.7	348	2025-12-31
Free cash flow growth, three-year compound	(8.0%)	12.5%	80.0	181	2025-12-31
Reinvestment rate	(15.0%)	19.3%	73.2	169	2025-12-31
Asset growth, three years	7.2%	2.8%	29.9	365	2025-12-31
Net share issuance, one year	0.0%	0.0%	49.0	316	2026-03-01

Among 329 peers

chemicals; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
72	Axcelis Technologies Inc. (ACLS)	23.7	B	
73	CSW Industrials, Inc. (CSW)	24.1	B	
74	AeroVironment Inc. (AVAV)	24.1	B	
75	Tennant Co. (TNC)	24.5	B	
76	Armstrong World Industries Inc. (AWI)	24.9	B	
77	United Guardian Inc. (UG)	25.0	B	
78	Griffon Corp. (GFF)	25.3	B	
79	ATI Inc. (ATI)	25.7	B	
80	Xylem Inc. (XYL)	26.1	B	
81	Carlisle Companies Inc. (CSL)	26.5	B	
82	Cabot Corp. (CBT)	26.8	B	

What the price implies

at the 2026-11-10 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	7.4%	10.9%	44
Distance from 52-week high	(6.2%)	(23.0%)	84
EBIT to enterprise value	not computable	3.7%	
Free cash flow yield	4.8%	3.3%	68
Book value to price	0.29	0.37	38
Sales to price	0.27	0.55	22
Composite equity issuance, five years	(31.5%)	(10.2%)	11

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Relative strength against the sector, log excess return	(0.07)	0.00	39

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	pass
Operating cash flow above zero	pass
Return on assets improved	fail
Operating cash flow exceeds net income	fail
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	pass
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	$2.4M
Operating cash flow, four quarters	$3.5M
Months of runway	not finite
Days since last periodic filing	93 (10-Q received Aug 11, 2026)
Median daily dollar volume, 63 sessions	$55,528

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	revenue	us-gaap:RevenueFromContractWithCustomerIncludingAs...	$10.5M	2025-12-31	2026-03-27	10-K	26-001973
2	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	$5.4M	2025-12-31	2026-03-27	10-K	26-001973
3	assets	us-gaap:Assets	$13.1M	2025-12-31	2026-03-27	10-K	26-001973
4	net income	us-gaap:NetIncomeLoss	$2.1M	2025-12-31	2026-03-27	10-K	26-001973
5	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$2.0M	2025-12-31	2026-03-27	10-K	26-001973
6	assets	us-gaap:Assets	$13.8M	2024-12-31	2026-03-27	10-K	26-001973
7	revenue	us-gaap:RevenueFromContractWithCustomerIncludingAs...	$12.2M	2024-12-31	2026-03-27	10-K	26-001973
8	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	$5.7M	2024-12-31	2026-03-27	10-K	26-001973
9	revenue	us-gaap:RevenueFromContractWithCustomerIncludingAs...	$10.9M	2023-12-31	2025-03-21	10-K	25-001611
10	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	$5.5M	2023-12-31	2025-03-21	10-K	25-001611
11	revenue	us-gaap:RevenueFromContractWithCustomerIncludingAs...	$12.7M	2022-12-31	2024-03-22	10-K	24-001526
12	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	$6.0M	2022-12-31	2024-03-22	10-K	24-001526
13	revenue	us-gaap:RevenueFromContractWithCustomerIncludingAs...	$13.9M	2021-12-31	2023-03-23	10-K	23-001846
14	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	$5.7M	2021-12-31	2023-03-23	10-K	23-001846
15	current assets	us-gaap:AssetsCurrent	$12.2M	2025-12-31	2026-03-27	10-K	26-001973
16	current liabilities	us-gaap:LiabilitiesCurrent	$1.7M	2025-12-31	2026-03-27	10-K	26-001973
17	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	$10.8M	2025-12-31	2026-03-27	10-K	26-001973
18	operating income	us-gaap:OperatingIncomeLoss	$2.2M	2025-12-31	2026-03-27	10-K	26-001973
19	book equity	us-gaap:StockholdersEquity	$11.2M	2025-12-31	2026-03-27	10-K	26-001973
20	liabilities	us-gaap:Liabilities	$1.9M	2025-12-31	2026-03-27	10-K	26-001973
21	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$58,995	2025-12-31	2026-03-27	10-K	26-001973
22	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$3.5M	2024-12-31	2026-03-27	10-K	26-001973
23	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$433,077	2024-12-31	2026-03-27	10-K	26-001973
24	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$3.1M	2023-12-31	2025-03-21	10-K	25-001611
25	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$165,716	2023-12-31	2025-03-21	10-K	25-001611
26	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$2.5M	2022-12-31	2024-03-22	10-K	24-001526
27	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$75,179	2022-12-31	2024-03-22	10-K	24-001526
28	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$108,200	2025-12-31	2026-03-27	10-K	26-001973
29	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	$2.6M	2025-12-31	2026-03-27	10-K	26-001973
30	income tax	us-gaap:IncomeTaxExpenseBenefit	$537,277	2025-12-31	2026-03-27	10-K	26-001973

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

31	current assets	us-gaap:AssetsCurrent	$12.7M	2024-12-31	2026-03-27	10-K	26-001973
32	current liabilities	us-gaap:LiabilitiesCurrent	$1.9M	2024-12-31	2026-03-27	10-K	26-001973
33	assets	us-gaap:Assets	$12.9M	2023-12-31	2025-03-21	10-K	25-001611
34	assets	us-gaap:Assets	$10.6M	2022-12-31	2024-03-22	10-K	24-001526
35	shares outstanding	dei:EntityCommonStockSharesOutstanding	4,594,319	2026-03-01	2026-03-27	10-K	26-001973
36	shares outstanding	dei:EntityCommonStockSharesOutstanding	4,594,319	2025-03-01	2025-03-21	10-K	25-001611

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.